Methods Of Modifying A Sequence Using CRISPR

• US 20160053272A1
• Filed: 07/16/2015
• Published: 02/25/2016
• Est. Priority Date: 07/18/2014
• Status: Abandoned Application

• Current Assignee: Whitehead Institute for Biomedical Research
• Original Assignee: Whitehead Institute for Biomedical Research
• Inventors: Reddien, Peter, Wurtzel, Omri, LoCascio, Samuel
• Application Number:
  US14/801,133
• Publication Number:
  US 20160053272A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: C12N 15/102 Mutagenizing nucleic acids
• CPC Class Codes: C12N 15/63 Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• CPC Class Codes: C12N 15/66 General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

Methods of modifying one or more target nucleic acid sequences using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR associated (Cas) proteins (CRISPR/Cas) system are disclosed. Methods of introducing one or more exogenous nucleic acid sequences into one or more circular nucleic acid sequences using the CRISPR/Cas system are also disclosed.

Claims

1. A method of modifying one or more target nucleic acid sequences comprising:

(a) contacting the one or more target nucleic acid sequences with;

i) one or more ribonucleic acid (RNA) sequences wherein each RNA sequence comprises a portion that is complementary to all or a portion of one or more of the target nucleic acid sequences;

ii) a CRISPR associated (Cas) protein having nuclease activity;

iii) one or more exogenous nucleic acid sequences wherein at least one exogenous nucleic acid sequence comprises a 5′

adapter sequence that hybridizes to a 5′

flanking sequence of the target nucleic acid sequence and at least one exogenous nucleic acid sequence comprises a 3′

adapter sequence that hybridizes to a 3′

flanking sequence of the target nucleic acid sequence; and

iv) a nucleic acid sequence that interacts with Cas protein;

thereby producing a combination; and

(b) maintaining the combination under conditions in which the one or more RNA sequences hybridize to all or the portion of the one or more target nucleic acid sequences to which each RNA sequence forms a complement thereby forming one or more base paired structures, and the one or more base paired structures and the nucleic acid sequence that interacts with Cas protein direct Cas protein to cleave the one or more target nucleic acid sequences;

thereby modifying the one or more target nucleic acid sequences.

2. The method of claim 1, wherein at least one exogenous nucleic acid sequence comprises one or more additional nucleotides.

3. The method of claim 1, wherein at least one exogenous nucleic acid sequences comprises a 5′

adapter sequence and a 3′

adapter sequence.

4. The method of claim 3, wherein the exogenous nucleic acid sequence further comprises one or more additional nucleotides between the 5′

adapter sequence and the 3′

adapter sequence.

5. The method of claim 1, further comprising contacting the combination with one or more exonucleases, polymerases and ligases.

8. The method of claim 2, wherein the one or more additional nucleotides is a gene, a regulatory sequence, a nucleotide variant, a restriction site, a cloning site, a recombination site, a RNA sequence, portions thereof, or combinations thereof.

13. The method of claim 2, wherein the exogenous nucleic acid sequence further comprises an additional nucleic acid sequence that encodes a polypeptide.

14. The method of claim 13, wherein the polypeptide is all or a portion of a tag, a transcription factor, an enzyme, a cytokine, a receptor, a transporter, a secreted protein, a binding protein, a post-translational modifying protein, a post-transcriptional modifying protein, a cytoskeletal protein, portions thereof, or combinations thereof.

18. The method of claim 1, wherein the one or more target nucleic acid sequences comprises a plasmid, a plastid, a bacterial nucleic acid, a bacterial artificial chromosome, a viral nucleic acid, a mitochondrial nucleic acid, or an artificially synthesized nucleic acid.

20. The method of claim 1, wherein the Cas protein is Cas9.

22. The method of claim 1, wherein the RNA sequence and the nucleic acid sequence that interacts with Cas protein are included in the same sequence.

6. (canceled)

7. (canceled)

9-12. -12. (canceled)

15-17. -17. (canceled)

19. (canceled)

21. (canceled)

23. (canceled)

24. (canceled)

25. A method of introducing one or more exogenous nucleic acid sequences into one or more circular nucleic acid sequences comprising:

(a) contacting the one or more circular nucleic acid sequences with;

i) one or more ribonucleic acid (RNA) sequences wherein each RNA sequence comprises a portion that is complementary to all or a portion of one or more target sequences within the one or more circular nucleic acid sequences;

ii) a CRISPR associated (Cas) protein having nuclease activity;

iii) one or more exogenous nucleic acid sequences wherein at least one exogenous nucleic acid sequence comprises a 5′

adapter sequence that hybridizes to a 5′

flanking sequence of the target nucleic acid sequence and at least one exogenous nucleic acid sequence comprises a 3′

adapter sequence that hybridizes to a 3′

flanking sequence of the target nucleic acid sequence;

wherein at least one exogenous nucleic acid sequence comprises one or more additional nucleotides; and

iv) a nucleic acid sequence that interacts with Cas protein;

thereby producing a combination; and

(b) maintaining the combination under conditions in which the one or more RNA sequences hybridize to all or the portion of the one or more target nucleic acid sequences to which each RNA sequence forms a complement thereby forming one or more base paired structures, and the one or more base paired structures and the nucleic acid sequence that interacts with Cas protein direct the Cas protein to cleave the target nucleic acid sequence;

thereby introducing the one or more exogenous nucleic acid sequence into the one or more circular nucleic acid sequences.

26. The method of claim 25, wherein at least one exogenous nucleic acid sequence comprises a 5′

adapter sequence and a 3′

adapter sequence.

27. The method of claim 26, wherein the exogenous nucleic acid sequence comprises the one or more additional nucleotides between the 5′

adapter sequence and the 3′

adapter sequence.

28. The method of claim 27, further comprising contacting the combination with one or more exonucleases, polymerases and ligases.

31. The method of claim 27, wherein the one or more additional nucleotides comprises a gene or portion thereof, a regulatory sequence, a nucleotide variant, a restriction site, a cloning site, a recombination site, a RNA sequence, portions thereof, or combinations thereof.

36. The method of claim 27, wherein the additional nucleotide comprises a nucleic acid sequence that encodes a polypeptide.

41. The method of claim 25, wherein the one or more circular nucleic acid sequences comprise a plasmid, a plastid, a bacterial nucleic acid, a bacterial artificial chromosome, a viral nucleic acid, a mitochondrial nucleic acid, or an artificially synthesized nucleic acid.

42. The method of claim 25, wherein the Cas protein is Cas9.

44. The method of claim 25, wherein the RNA sequence and the nucleic acid that interacts with Cas protein are on the same sequence.

29. (canceled)

30. (canceled)

32-35. -35. (canceled)

37-40. -40. (canceled)

43. (canceled)

45. (canceled)

46. (canceled)